Thyroid eye disease is an autoimmune inflammatory disorder that can be vision-threatening and disfiguring.
New medical therapies are emerging to prevent and treat the disabling consequences of the disease.
We are involved in multiple clinical trials aimed at providing targeted therapy for TED.
Treatment costs are covered for patients who meet criteria for enrollment in Clinical Trials
This is a research study to evaluate how safe and effective VRDN-001 intravenous infusions are as a potential treatment for Thyroid Eye Disease. An infusion is delivering the study drug into a vein in your arm.
Viridian Therapeutics, Inc is a biotechnology company advancing new treatments suffering Thyroid Eye Disease (TED) underserved by current therapies.
You will be compensated for your time and travel
3590 Camino Del Rio North
Ste 200
San Diego, CA 92108
Kimberly Cockerham, MD, FACS
Principal Investigator, Thyroid Eye Disease Clinical Trials
Neuro-ophthalmology, Oculofacial plastic Surgery & Orbital Oncology
Christina Douglas, MD
Fellow, Clinical Research Assistant
Neuro-ophthalmology, Oculofacial plastic Surgery & Orbital Oncology
Rocio Gonzalez Beristain, MS, MPH
Clinical Research Coordinator
VRDN-001 Clinical Study
Karen and Nate
Medical Assistants
Brittany
Front Office Coordinator